Gemcitabine plus nab‐paclitaxel versus FOLFIRINOX for unresected pancreatic cancer: Comparative effectiveness and evaluation of tumor growth in Veterans-Reference-Cited by-同舟云学术

Gemcitabine plus nab‐paclitaxel versus FOLFIRINOX for unresected pancreatic cancer: Comparative effectiveness and evaluation of tumor growth in Veterans

Published:2021-02 Issue:1 Volume:48 Page:69-75
ISSN:0093-7754
Container-title:Seminars in Oncology
language:en
Short-container-title:Seminars in Oncology

Author:

Sigel Keith^ORCID,Zhou Mengxi,Park Yeun-Hee Anna,Mutetwa Tinaye,Nadkarni Girish,Yeh Celine,Polak Paz,Sigel Carlie,Conroy Thierry,Juzyna Béata,Ychou Mark,Fojo Tito,Wisnivesky Juan P,Bates Susan E.

Publisher

Elsevier BV

Subject

Oncology,Hematology

Reference21 articles.

1. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States;Rahib;Cancer Res,2014

2. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer;Conroy;N Engl J Med,2011

3. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine;Von Hoff;N Engl J Med,2013

4. Current status on the place of FOLFIRINOX in metastatic pancreatic cancer and future directions;Lambert;Therap Adv Gastroenterol,2017

5. Clinical outcomes with first-line chemotherapy in a large retrospective study of patients with metastatic pancreatic cancer treated in a US community oncology setting;Cartwright;Drugs Real World Outcomes,2018

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Novel therapeutic strategies in pancreatic cancer: moving beyond cytotoxic chemotherapy;Expert Review of Anticancer Therapy;2023-10-19

2. Folfirinox vs. Gemcitabine + Nab-Paclitaxel as the First-Line Treatment for Pancreatic Cancer: A Systematic Review and Meta-Analysis;World Journal of Oncology;2023-10

3. Tumor Growth Rate Informs Treatment Efficacy in Metastatic Pancreatic Adenocarcinoma: Application of a Growth and Regression Model to Pivotal Trial and Real-World Data;The Oncologist;2022-11-11

4. Validation of SFRP1 Promoter Hypermethylation in Plasma as a Prognostic Marker for Survival and Gemcitabine Effectiveness in Patients with Stage IV Pancreatic Adenocarcinoma;Cancers;2021-11-15

5. Two decades of research toward the treatment of locally advanced and metastatic pancreatic cancer: Remarkable effort and limited gain;Seminars in Oncology;2021-02